Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest EXPAREL Stories

2014-02-21 08:25:52

Dr. Rian A. Maercks adds anesthetic Exparel to his innovative Cold-Subfascial Breast AugmentationR procedure to deliver patients "unaugmented" appearance with a pain free experience MIAMI, Feb. 21, 2014 /PRNewswire/ -- The Maercks Institute announced the addition of the new long-term local anesthetic Exparel to the elite Cold-Subfascial Breast AugmentationR today. This novel application of Exparel allows breast augmentation patients to have a painless breast augmentation recovery....

2012-10-13 04:04:32

IMPROVE trial compares the cost of care between a standard opioid-based regimen and an EXPAREL-based multimodal regimen for postsurgical pain management. Online (PRWEB) October 11, 2012 PARSIPPANY, N.J.-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced topline results from the first completed IMPROVE study in its prospective Phase 4 clinical program. The study was designed to compare the difference in three primary endpoints–cost, opioid consumption and hospital length of...

2011-12-19 05:30:00

PARSIPPANY, N.J., Dec. 19, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced the publication of data from a placebo-controlled, pivotal Phase 3 trial of EXPAREL(TM) (bupivacaine liposome injectable suspension), a non-opioid local analgesic that was recently approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia. The results, which demonstrate statistically significantly...

2011-10-31 05:32:00

PARSIPPANY, N.J., Oct. 31, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration's (FDA) approval of EXPAREL(TM) (bupivacaine liposome injectable suspension) and the commercial strategy to support the product launch. "With the broad postsurgical pain management label granted by the FDA,...

2011-10-11 05:30:00

PARSIPPANY, N.J., Oct. 11, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that new data highlighting the pain control and pharmacokinetic properties of EXPAREL(TM) (bupivacaine liposome extended-release injectable suspension), the company's lead investigational product for postsurgical pain management, will be presented during poster presentations at the 2011 Annual Meetings of the American Society of Anesthesiologists (ASA) and the American College of...

2011-09-26 05:30:00

DENVER and PARSIPPANY, N.J., Sept. 26, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that the company's lead investigational product for postsurgical pain management, EXPAREL(TM) (bupivacaine liposome extended-release injectable suspension), was highlighted in the "Hot Topics in Plastic Surgery" panel at the annual scientific assembly of the American Society of Plastic Surgeons (ASPS) in Denver, Colo. In addition, new data demonstrating the long-term...

2011-08-02 05:30:00

PARSIPPANY, N.J., Aug. 2, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that new preclinical data evaluating the safety of DepoFoam® with DEPC (a novel excipient) will be presented in two podium sessions at the 38th Annual Meeting & Exposition of the Controlled Release Society (CRS) in National Harbor, Md. DepoFoam is Pacira's proprietary, extended release drug delivery technology,...

2011-05-23 05:30:00

PARSIPPANY, N.J., May 23, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that clinical data highlighting the safety profile of EXPAREL(TM) (bupivacaine extended-release liposome injection) will be presented at the 2011 International Anesthesia Research Society (IARS) Annual Meeting in Vancouver, British Columbia. Comprehensive, program-wide safety data for EXPAREL will be presented by Dr. Eugene R....

2011-05-11 05:30:00

PARSIPPANY, N.J., May 11, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), an emerging specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL(TM), and reiterated 2011 financial guidance. "During the first quarter we have continued to work closely with hospitals and physicians to evaluate the clinical and favorable economic...

2011-05-05 15:05:00

PARSIPPANY, N.J., May 5, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that clinical and preclinical data highlighting the safety and efficacy of EXPAREL(TM) will be presented at two medical meetings. New Phase 3 data on the use of EXPAREL in the treatment of postsurgical pain after augmentation mammoplasty will be presented by Sergio Bergese, M.D., associate professor of anesthesiology and neurological...